openPR Logo
Press release

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report

05-07-2018 08:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Immunotoxins Market & Clinical Pipeline Insight

“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:

* Introduction to Immunotoxins
* Cancer Immunotoxins Therapy Analysis
* Advantages of Immunotoxins upon other Anticancerous Drugs
* Applications of Immunotoxins to Multiple Cancer Therapies
* Global Cancer Immunotoxins Market Future Prospects
* Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
* Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
* Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Immunotoxins



2. Immunotoxins: The Three Generations & Advancements



3. Sources of Toxins

3.1 Plant Toxins

3.2 Bacterial Toxins



4. Production of Immunotoxins



5. Types of Immunotoxins

5.1 Anthrax Based Toxins

5.2 Diphtheria Toxin (DT) & DT Derivatives

5.3 Pseudomonas Exotoxin (PE) & PE Derivatives

5.4 Ribosome Inactivating Proteins Based Immunotoxins

5.4.1 Ricin

5.4.2 Saporin based Immunotoxins

5.4.3 Recombinant Constructs of RIP I Toxins

5.5 Ribonucleases based Immunotoxins

5.6 Proapoptotic Proteins as Targeted Immunotoxins



6. Cancer Immunotoxins Therapy Analysis

6.1 Immunotoxins for Hematologic Malignancies

6.1.1 Denileukin Diftitox (ONTAK, DAB389IL-2)

6.1.2 LMB-2 (anti-Tac[Fv]-PE38)

6.1.3 Moxetumomab Pasudotox

6.1.4 A-dmDT390-bisFv (UCHT1)

6.1.5 DT2219ARL

6.1.6 HuM195-Gelonin

6.2 Immunotoxins for Solid Tumors

6.2.1 SS1P

6.2.2 RG7787

6.2.3 Oportuzumab Monatox

6.2.4 VB6-845

6.2.5 D2C7-(scdsFv)-PE38KDEL



7. Advantages of Immunotoxins upon other Anticancerous Drugs



8. Applications of Immunotoxins

8.1 Immunotoxins against Solid Tumors

8.1.1 Immunotoxin against Colon Carcinoma

8.1.2 Immunotoxin against Breast Cancer & Sarcoma

8.1.3 Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma

8.1.4 Immunotoxin against Prostate & Lung Cancer

8.2 Immunotoxins against Leukemias

8.3 Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs



9. Global Cancer Immunotoxins Market Outlook

9.1 Current Market Scenario

9.2 Cancer Immunotoxins Clinical Pipeline Overview



10. Global Cancer Immunotoxins Market Dynamics

10.1 Favorable Parameters

10.1.1 Large Segment of Patient Still Devoid of Appropriate Medication

10.1.2 Cancer: A Severe Pathological Condition

10.1.3 Unmet Requirement of Completely Curative Agents

10.1.4 Unwanted Effects of the Existing Drugs

10.2 Commercialization Challenges

10.2.1 Stern Regulatory Guidelines: A Major Hurdle

10.2.2 Never Ending Phase of Research & Development

10.2.3 Conduction of Clinical Trials

10.2.4 Funding Research & Development: A Super Costly Affair

10.2.5 Immunogenicity of Immunotoxins



11. Global Cancer Immunotoxins Market Future Prospects



12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

12.1 Research

12.2 Preclinical

12.3 Phase-I

12.4 Phase-I/II

12.5 Phase-II

12.6 Phase-II/III

12.7 Phase-III



13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

13.1 No Development Reported

13.2 Discontinued

13.3 Suspended



14. Competitive Landscape

14.1 AbbVie

14.2 AbGenomics

14.3 Agensys

14.4 Ambrx

14.5 Amgen

14.6 AREVA Med

14.7 Bayer HealthCare

14.8 Biotest

14.9 Celldex Therapeutics

14.10 CuraGen Corporation

14.11 Genentech

14.12 Genmab

14.13 Heidelberg Pharma

14.14 ImmunoGen

14.15 Neurocrine Biosciences

14.16 Research Corporation Technologies

14.17 Sanofi

14.18 Seattle Genetics

14.19 Sorrento Therapeutics

14.20 Spirogen

Figure 2-1: Immunotoxins & Their Recombinant Forms

Figure 3-1: Sources of Toxins

Figure 4-1: Steps Involved in Production of Immunotoxins

Figure 5-1: Different Types of Immunotoxins

Figure 5-2: Mechanism of Action of Anthrax Based Immunotoxins

Figure 5-3: Composition of the Diphtheria Derived Toxins

Figure 5-4: Steps Involved in Apoptosis by Diphtheria Derived Immunotoxins

Figure 5-5: Domains of PE with Their Specificities

Figure 5-6: Mode of Apoptosis Taken by Pseudomonas Exotoxin (PE) & PE Derivatives

Figure 6-1: Major Targets of Immunotoxins as Anticancer Agents

Figure 6-2: Some of Important Immunotoxins Targeting Hematological Malignancies

Figure 6-3: Some of Important Immunotoxins Targeting Solid Tumors

Figure 8-1: Major Applications of Immunotoxins

Figure 9-1: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-2: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 9-3: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-4: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 10-1: Favorable Parameters for Global Cancer Immunotoxins Market

Figure 10-2: Commercialization Challenges for Global Cancer Immunotoxins Market

Figure 14-1: AbGenomics - Clinical Pipeline

Figure 14-2: Amgen - Clinical Pipeline

Figure 14-3: Biotest – Clinical Pipeline

Figure 14-4: Genmab - Clinical Pipeline

Figure 14-50: Genmab - Clinical Pipeline

Figure 14-6: Neurocrine Biosciences – Clinical Pipeline

Figure 14-7: Sorrento Therapeutics – Clinical Pipeline



Table 5-1: Immunotoxins in Clinical Development using Diphtheria as a Toxin Moiety

Table 5-2: Clinically evaluated/under evaluation PE-based Immunotoxins against Hematologic Malignancies

Table 5-3: Clinically evaluated/under evaluation PE-based Immunotoxins against Solid Tumors

Table 5-4: Clinical Trials in Patients with Saporin Containing Immunotoxins

Table 6-1: Immunotoxins for Leukemia

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report here

News-ID: 1040840 • Views: 250

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Immunotoxin

Global Immunotoxins Market - Industry Size, Share, Growth, Trends and Forecast 2 …
"The Report Immunotoxins Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin.
Download Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Repo …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. The cytotoxic part
Immunotoxins Market Research Report | Growth Prospects, Key Opportunities, Trend …
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Cancer Immunotoxins Market Cancer Immunotoxins Clinical Pipeline Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Immunotoxins 2. Immunotoxins: The Three Generations & Advancements 3. Sources of Toxins 3.1 Plant Toxins 3.2 Bacterial Toxins 4. Production of Immunotoxins 5. Types of Immunotoxins 5.1 Anthrax Based Toxins 5.2 Diphtheria Toxin (DT) & DT Derivatives 5.3 Pseudomonas Exotoxin (PE) & PE Derivatives 5.4 Ribosome Inactivating Proteins Based Immunotoxins
Immunotoxins Market: Industry Overview and Key Factors
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Global Cancer Immunotoxins Market Sales Revenue Clinical Trials Pipeline Report …
Immunotoxins are new generation chemotherapeutic agents innovated to include the specificity of monoclonal antibody and cytotoxicity of toxins extracted from plant or bacterial source. The targeting moiety carries the specificity of the antibody and is directed to the target where it either binds to the cell surface antigen, receptor or the ligand of the targeted disease. Cytotoxicity is mediated by the protein toxins, which maybe protein at times. Download Report: https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php For Report